Fluoxetine vs Paroxetine: Nutrient Depletion Comparison
Compare YOUR medications' depletionsFree, 10 seconds →
At a Glance
Fluoxetine inhibits the serotonin transporter while also directly suppressing pineal AANAT enzyme activity — the rate-limiting step in melatonin synthesis. CTD documents 211 gene interactions, the broadest SSRI molecular footprint, spanning serotonin receptors, sigma receptors, ion channels, and multiple CYP enzymes. This wide binding profile means fluoxetine affects more biological pathways than just serotonin reuptake, increasing folate demand through accelerated monoamine turnover and triggering SIADH-mediated sodium wasting, though less aggressively than paroxetine.
Fluoxetine achieves 90% bioavailability with a 48-hour half-life, and its active metabolite norfluoxetine extends to 4–16 days — effectively creating continuous serotonergic coverage that eliminates discontinuation syndrome but also means nutrient depletion never pauses.
- ✓Virtually zero discontinuation syndrome — the easiest SSRI to stop taking
- ✓Five FDA indications: depression, OCD, panic disorder, bulimia nervosa, and PMDD
- ✓ChEMBL documents 429 RCTs across 238,071 patients — the most studied antidepressant ever
- ✓Lower SIADH risk than paroxetine — less dangerous for sodium depletion in elderly patients
- ✗211 CTD gene interactions indicate the broadest off-target molecular footprint of any SSRI
- ✗Potent CYP2D6 inhibition blocks metabolism of codeine, tamoxifen, and many co-medications
- ✗Direct pineal AANAT suppression makes insomnia more common than with paroxetine
- ✗94% protein binding creates displacement risks with warfarin and other highly-bound drugs
Patients with multiple psychiatric conditions, those who need withdrawal-proof pharmacokinetics, or anyone who prioritizes medication adherence over sleep quality.
Paroxetine is the most potent serotonin reuptake inhibitor in the SSRI class, with additional anticholinergic and histaminergic binding that expands its side effect profile. CTD documents 51 gene interactions — fewer than fluoxetine's 211 but still substantial, including genes involved in SIADH regulation that explain its uniquely high hyponatremia risk. Paroxetine's aggressive serotonin transporter binding means more folate consumption through BH4-dependent synthesis, and its 95% protein binding creates drug displacement risks rivaling fluoxetine's 94%.
Paroxetine reaches 45% bioavailability with a 17–22 hour half-life and nonlinear pharmacokinetics — small dose increases create disproportionately large blood level changes, making it both the most potent and the least predictable SSRI to dose.
- ✓Broadest SSRI indication list: depression, GAD, panic, OCD, PTSD, social anxiety, and hot flashes
- ✓Most potent serotonin transporter binding — effective when other SSRIs have failed
- ✓ChEMBL documents 254 RCTs across 120,623 patients with proven efficacy across anxiety spectrum
- ✓Less aggressive melatonin suppression than fluoxetine — better sleep preservation
- ✗Highest SIADH risk of any SSRI — the most dangerous SSRI for sodium depletion in elderly patients
- ✗One of the worst SSRI discontinuation syndromes due to short half-life and nonlinear kinetics
- ✗Significant anticholinergic effects: dry mouth, constipation, cognitive dulling, weight gain
- ✗Potent CYP2D6 inhibition parallels fluoxetine's — both block metabolism of many co-medications
Patients with treatment-resistant anxiety disorders, hot flashes, or those who need the most powerful available serotonin reuptake inhibition and can tolerate anticholinergic side effects.
Feature Comparison
| Feature | Fluoxetine | Paroxetine |
|---|---|---|
| Drug Class | SSRI (broad binding profile) | SSRI (most potent SRI + anticholinergic) |
| Nutrients Depleted | 3 — sodium, folate, melatonin | 3 — sodium, folate, melatonin |
| CTD Gene Interactions | 211 documented | 51 documented |
| Half-Life | 48 hours (norfluoxetine 4–16 days) | 17–22 hours (nonlinear) |
| Worst Depletion Risk | Melatonin (direct pineal suppression) | Sodium (highest SIADH risk) |
| Protein Binding | 94% | 95% |
| Discontinuation Severity | Minimal (self-tapering) | Severe (brain zaps, emotional lability) |
| FDA Indications | 5 — depression, OCD, panic, bulimia, PMDD | 7 — depression, GAD, panic, OCD, PTSD, social anxiety, hot flashes |
Wondering which medication depletes less?
Check your medications free — 10 seconds →Verdict
These two SSRIs deplete the same three nutrients but attack from different angles. Fluoxetine's 211 CTD gene interactions and direct pineal AANAT suppression make melatonin depletion and insomnia its primary liability, while paroxetine's position as the highest SIADH-risk SSRI makes sodium depletion its most dangerous concern — especially in patients over 65. Both potently inhibit CYP2D6 and have near-identical protein binding (94% vs 95%). The tiebreaker is often discontinuation: fluoxetine's 48-hour half-life makes it virtually withdrawal-proof, while paroxetine's nonlinear 17-hour half-life creates one of psychiatry's worst discontinuation syndromes. For patients who may need to stop their SSRI, fluoxetine is definitively safer. For patients with the most treatment-resistant anxiety across multiple disorders, paroxetine's seven FDA indications and unmatched serotonin transporter potency give it a unique clinical role.
FAQ
References
- [1]CTD (Comparative Toxicogenomics Database): 211 gene interactions for fluoxetine; 51 gene interactions for paroxetine including SIADH-related pathway genes
- [2]ChEMBL bioactivity database: 429 RCTs for fluoxetine (238,071 patients); 254 RCTs for paroxetine (120,623 patients)
- [3]FAERS (FDA Adverse Event Reporting System): fluoxetine 2,659 reports; paroxetine 2,002 reports with higher SIADH-related event rates
- [4]PharmGKB pharmacogenomics database: both classified as strong CYP2D6 inhibitors with Level 1A pharmacogenomic evidence
- [5]PubMed PMID 19185342 — Cipriani A et al. Comparative efficacy and acceptability of 12 new-generation antidepressants. Lancet. 2009;373(9665):746-758
Check your medications
Check Free →